Results 21 to 30 of about 64,955 (112)

An alternative dosing strategy for ropeginterferon alfa-2b may help improve outcomes in myeloproliferative neoplasms: An overview of previous and ongoing studies with perspectives on the future

Frontiers in Oncology, 2023
Ropeginterferon alfa-2b is a novel, long-acting mono-pegylated proline-IFN-alpha-2b approved for treatment of polycythemia vera in adults, regardless of thrombotic risk level or treatment history.
A. Qin, Raymond W Urbanski, L. Yu, Tasfia Ahmed, J. Mascarenhas   +4 more
semanticscholar   +1 more source

Genetic characterization of the ALFA study: Uncovering genetic profiles in the Alzheimer's continuum

medRxiv, 2023
In 2013, the ALzheimer's and FAmilies (ALFA) project was established to investigate pathophysiological changes in preclinical Alzheimer's disease (AD), and to foster research on early detection and preventive interventions.
N. Vilor-Tejedor, P. Genius, B. Rodríguez‐Fernández, C. Minguillón, Iman Sadeghi, A. González-Escalante, M. Crous-Bou, M. Suárez‐Calvet, O. Grau-Rivera, A. Brugulat-Serrat, G. Sánchez-Benavides, Manel Esteller, K. Fauria, J. Molinuevo, A. Navarro, J. Gispert   +15 more
semanticscholar   +1 more source

Event-free survival in patients with polycythemia vera treated with ropeginterferon alfa-2b versus best available treatment

Leukemia, 2023
)
H. Gisslinger, C. Klade, P. Georgiev, D. Krochmalczyk, L. Gercheva‐Kyuchukova, M. Egyed, P. Dulíček, Á. Illés, H. Pylypenko, L. Sivcheva, J. Mayer, V. Yablokova, K. Krejcy, V. Empson, H. Hasselbalch, R. Kralovics, J. Kiladjian, Heinz Jean-Jacques Gisslinger Kiladjian, H. Gisslinger, J. Kiladjian   +19 more
semanticscholar   +1 more source

Prevalence of anaemia and its clinical management in patients with stages 3-5 chronic kidney disease not on dialysis in Catalonia: MICENAS I study [PDF]

, 2018
Introducción: La anemia es una complicación frecuente de la enfermedad renal crónica (ERC). El objetivo de este estudio fue conocer la prevalencia de anemia en pacientes con ERC estadios 3-5 no en diálisis atendidos en consultas externas (CCEE) de ...
Bonal, Jordi, Cases Amenós, A. (Aleix), Coll Piera, Elisabeth, Fort, Joan, Galceran, Josep M., Investigadores del Estudio Micenas I., Martínez Castelao, Alberto, Ruiz, Pilar, Vallès Prats, Martí   +8 more
core   +1 more source

Estudio Coste-Eficacia de dos Estimulantes Eritropoyéticos para el Tratamiento de la Anemia en Pacientes con Insuficiencia Renal Crónica en Hemodiálisis: Epoetinum Alfa y Darbepoetina Alfa

, 2004
El tratamiento por excelencia de la anemia en pacientes con insuficiencia renal crónica en programa de hemodiálisis es, desde su aparición en el mercado, la eritropoyetina humana recombinante.
Antonia Alfaro Cuenca, Berta Gallego Jordán, M. Piñero   +2 more
semanticscholar   +1 more source

Adherencia al tratamiento con agentes estimulantes de la eritropoyesis [PDF]

, 2020
Fundamento. Determinar la adherencia al tratamiento con agentes estimulantes de la eritropoyesis (AEE) en pacientes con anemia asociada a enfermedad renal crónica (ERC), y valorar su relación con la respuesta frente a estos AEE.
Lou Arnal, L.M., Navarro Aznárez, H., Perez Díez, C.   +2 more
core   +1 more source

Roxadustat Versus Epoetin Alfa for Treating Anemia in Patients with Chronic Kidney Disease on Dialysis: Results from the Randomized Phase 3 ROCKIES Study

Journal of the American Society of Nephrology, 2022
Significance Statement Iron supplementation and erythropoiesis-stimulating agents (ESAs) are currently recommended for treating anemia in patients with dialysis-dependent (DD)-CKD.
S. Fishbane, C. Pollock, M. El-Shahawy, E. Escudero, A. Rastogi, Bui Pham Van, L. Frison, M. Houser, Maksym Pola, D. Little, Nicolas Guzman, P. Pergola   +11 more
semanticscholar   +1 more source

Costes de los agentes estimulantes de la eritropoyesis en el tratamiento de la anemia inducida por quimioterapia en España: resultados preliminares procedentes de la adaptación de un estudio belga

, 2014
ResumenObjetivosSpaepen y cols. (The Oncologist 13:596–607, [2008]) compararon el coste de manejo de la anemia inducida por quimioterapia en pacientes tratados con darbepoetina-alfa (DARB), epoetina-alfa (EPO-A) y epoetina-beta (EPO-B) en Bélgica.
Á. Durán, Erik Spaepen, M. Lamotte, M. Brosa, Laura Gutiérrez, G. Restovic   +5 more
semanticscholar   +1 more source

Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b

Leukemia, 2022
TO THE EDITOR: Interferon alfa not only restores normal blood cell counts in patients with polycythemia vera (PV) but can diminish the mutant JAK2 V617F allele burden [1 – 3].
J. Kiladjian, C. Klade, P. Georgiev, D. Krochmalczyk, L. Gercheva‐Kyuchukova, M. Egyed, P. Dulíček, Á. Illés, H. Pylypenko, L. Sivcheva, J. Mayer, V. Yablokova, K. Krejcy, V. Empson, H. Hasselbalch, R. Kralovics, H. Gisslinger, Jean-Jacques Pencho Dorota Liana Miklos Petr Arpad Halyna Lylia Kiladjian Georgiev Krochmalczyk Gercheva-Kyuchukov, J. Kiladjian   +18 more
semanticscholar   +1 more source

Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhage: a propensity score-overlap weighted analysis

Critical Care, 2022
Background Andexanet alfa is approved (FDA “accelerated approval”; EMA “conditional approval”) as the first specific reversal agent for factor Xa (FXa) inhibitor-associated uncontrolled or life-threatening bleeding.
O. S. Costa, S. Connolly, Mukul Sharma, J. Beyer-Westendorf, M. Christoph, B. Lovelace, C. Coleman   +6 more
semanticscholar   +1 more source